Biotricity Expands IP Portfolio & Strategy with 14 New Patents, Reinforcing Innovation & Leadership in Remote Monitoring, Diagnostics, & Chronic Disease Management

Stock Information for Immuron Limited

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Immuron Limited

Biotricity Recognized by Financial Times as One of 2025's Fastest-Growing Companies in the Americas, Growing 256.4% Over the Period Analyzed
Biotricity Delivers Record Margins, Record Revenues, and Record Cashflows with 21.7% Year-Over-Year Sales Growth for its Third Quarter of Fiscal 2025
Biotricity Announces Cashflow Breakeven with Biggest Quarter in History and a Revenue Increase of 11%
Biotricity and B-Secur Partner to Launch the Most Comprehensive Device-Neutral Ambulatory Cardiac Monitoring Platform
Biotricity Produces Largest Inventory in its History to Meet Accelerated Demand
Biotricity Achieves Positive Free Cash Flow Milestone
Biotricity Achieves Improved Margins and Efficiencies, and Year-Over-Year Sales Growth for Second Quarter of Fiscal Year 2025 
Biotricity to Host Second Quarter Fiscal Year 2025 Financial Results and Business Update Call on November 15th

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.